TL1A-Fc

TL1A-Fc (also known as Fc-TL1A or Fc-scTL1A) is a recombinant fusion protein consisting of the tumor necrosis factor (TNF) superfamily ligand TL1A (TNFSF15) genetically fused to an immunoglobulin Fc domain. It acts as a potent agonist of death receptor 3 (DR3, TNFRSF25), a receptor highly expressed on regulatory T cells (Tregs) and conventional T cells. By engaging DR3, TL1A-Fc promotes the expansion and activation of the endogenous Treg pool, restoring tissue homeostasis and immunotolerance. Preclinical research, notably conducted by the University of Würzburg, TrimmunoTec, and Dualyx, has demonstrated that TL1A-Fc treatment can significantly expand Tregs and prevent acute graft-versus-host disease (aGvHD) in animal models of allogeneic hematopoietic cell transplantation (allo-HCT). Additionally, TL1A-Fc is widely utilized as a research-use-only reagent to study mucosal immunity, T-cell costimulation, and inflammatory pathways.

Other names

Fc-TL1AFc-TL-1AFc-TL 1AFc-scTL1AFc-scTL-1AFc-scTL 1Arecombinant TL1A-Fc fusion protein